Fractal pharmacokinetics of the drug mibefradil in the liver.
We explore the ramifications of the fractal geometry of the key organ for drug elimination, the liver, on pharmacokinetic data analysis. A formalism is developed for the use of a combination of well-stirred Euclidean and fractal compartments in the body. Perturbation analysis is carried out to obtain analytical solutions for the drug concentration time evolution. These results are then fitted to experimental data collected from clinically instrumented dogs [see, A. Skerjanec et al., J. Pharm. Sci. 85, 189 (1995)] using the drug mibefradil. The thus obtained spectral fractal dimension has a range of values that is consistent with the value found in independently performed ultrasound experiments on the liver.
Fuite
J
J
Department of Physics, University of Alberta, Edmonton AB, T6G 2J1, Canada.
Marsh
R
R
Tuszyński
J
J
D000818:Animals; D004285:Dogs; D017709:Fractals; D007700:Kinetics; D008099:Liver / Q000187:drug effects*; D020748:Mibefradil / Q000493:pharmacokinetics*; D008954:Models, Biological; D015233:Models, Statistical; D013997:Time Factors
D020748:Mibefradil